Stoke Therapeutics Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Ian Smith
Chief executive officer
US$248.3k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 2.6yrs |
| Board average tenure | 6.6yrs |
Recent management updates
Recent updates
Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be
Apr 16
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Apr 05We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Feb 26Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
Feb 16Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts
Nov 08Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts
Nov 06Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
Sep 07We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Jul 22Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Jun 14It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope
May 30Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
Apr 04Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation
Mar 21We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Dec 07Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts
May 09Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results
May 06Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business
May 02We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow
Dec 13Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth
Aug 14Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M
Aug 08CEO
Ian Smith (58 yo)
less than a year
Tenure
US$248,254
Compensation
Mr. Ian F. Smith, CPA, ACA, is Director of Areteia Therapeutics, Inc. from March 26, 2025. He is an Interim CEO of Stoke Therapeutics, Inc. from March 19, 2025. He is an Independent Director at Odyssey The...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim Executive Chairman | 6.6yrs | US$150.65k | 0.059% $ 309.8k | |
| Interim CEO & Director | less than a year | US$248.25k | no data | |
| Co-Founder & Independent Director | no data | US$130.95k | 0.75% $ 4.0m | |
| Chief Financial Officer | less than a year | US$4.69m | no data | |
| Advisor & Director | less than a year | US$5.61m | 0.26% $ 1.4m | |
| Chief Medical Officer | 7.5yrs | US$2.47m | 0.11% $ 591.7k | |
| Co-Founder | no data | no data | no data | |
| Director of Communications & Investor Relations | less than a year | no data | no data | |
| Corporate Secretary & General Counsel | 4.3yrs | no data | 0.058% $ 308.1k | |
| Chief Communications Officer | 4.3yrs | no data | no data | |
| Chief Human Resources Officer | 5.5yrs | no data | no data | |
| Senior VP of Quality & Chief Regulatory Affairs Officer | 6.3yrs | no data | no data |
2.6yrs
Average Tenure
59.5yo
Average Age
Experienced Management: STOK's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim Executive Chairman | 6.6yrs | US$150.65k | 0.059% $ 309.8k | |
| Interim CEO & Director | 1.6yrs | US$248.25k | no data | |
| Co-Founder & Independent Director | 10.8yrs | US$130.95k | 0.75% $ 4.0m | |
| Advisor & Director | 7.5yrs | US$5.61m | 0.26% $ 1.4m | |
| Independent Director | 9.8yrs | US$237.33k | 3.47% $ 18.3m | |
| Independent Director | 9.6yrs | US$135.95k | 0.035% $ 187.3k | |
| Independent Director | 4.7yrs | US$136.14k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$137.39k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$140.95k | 0% $ 0 |
6.6yrs
Average Tenure
61yo
Average Age
Experienced Board: STOK's board of directors are considered experienced (6.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/28 08:05 |
| End of Day Share Price | 2025/04/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Stoke Therapeutics, Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Thomas Shrader | BTIG |
| Michelle Gilson | Canaccord Genuity |